Key Metrics of Immuron Limited
Market cap$7.7MIMRN · $0.95
Competitors10identified
About Immuron Limited
Sectors
Company details
- Founded
- 2017
- Listed
- Nasdaq: IMRN (since 2017)
Operational Areas of Immuron Limited
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameImmuron Limited
TickerIMRN
ExchangeNasdaq
CountryAustralia
SEC CIK0001660046
Listed since2017
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
IMRN · Nasdaq · SEC CIK 0001660046
Last price · 24 Oct 2026
$0.95
−2.13%
Market cap$7.7M
P/E—
Volume15,728
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOAustraliaListed 2017
IMRN share price
Annual results (SEC EDGAR)
No annual results in SEC XBRL data for this company yet.
Vendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Immuron Limited
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.